| $376M | ||
| $350M | ||
| $215M | ||
| $107M | ||
| $100M | ||
| $99M |
Buys | $104,925 | 1 | 17 |
Sells | $37,044,057 | 5 | 83 |
| Vu Quan Anh | Chief Financial Officer | 1 | $104,925 | 0 | $0 | $104,925 |
| KLAUSNER ARTHUR J | director | 0 | $0 | 1 | $343,889 | $-343,889 |
| Tsuchimoto Kim R | director | 0 | $0 | 1 | $356,171 | $-356,171 |
| Robinson Chandler | Chief Executive Officer | 0 | $0 | 1 | $672,020 | $-672,020 |
| STARR CHRISTOPHER M | director | 0 | $0 | 1 | $672,020 | $-672,020 |
| Tactic Pharma LLC | 10 percent owner | 0 | $0 | 1 | $35M | $-35M |
Monopar Therapeutics Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to pioneering novel cancer treatments within the United States. Its leading investigational drug, Validive, a specialized clonidine hydrochloride mucobuccal tablet, is currently undergoing Phase 2b/3 clinical trials. This therapy aims to prevent severe oral mucositis, a debilitating side effect of chemoradiotherapy, in patients suffering from oropharyngeal cancer. The company's pipeline also includes Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trials for advanced soft tissue sarcoma. Furthermore, Monopar is developing MNPR-101, an antibody engineered to target the urokinase plasminogen activator receptor (uPAR) for various cancer indications. A radioimmunotherapeutic variant of MNPR-101, named MNPR-101 RIT, is being explored for its potential in both cancer therapy and the treatment of severe COVID-19. Another promising compound, MNPR-202, an analog of camsirubicin, is being developed to potentially address cancers that have developed resistance to doxorubicin and camsirubicin. Monopar Therapeutics Inc. maintains strategic partnerships, including one with the Grupo Español de Investigación en Sarcomas (GEIS) for the advancement of camsirubicin in patients with advanced soft tissue sarcoma. They also collaborate with NorthStar Medical Radioisotopes, LLC on the development of radio-immunotherapeutics targeting severe COVID-19, and with the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related compounds across different cancer types. The company was established in 2014 and its corporate headquarters are situated in Wilmette, Illinois.
Over the last 12 months, insiders at Monopar Therapeutics Inc. have bought $104,925 and sold $37.04M worth of Monopar Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Monopar Therapeutics Inc. have bought $69,943 and sold $19.11M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Vu Quan Anh (Chief Financial Officer) — $104,925.
The last purchase of 1,500 shares for transaction amount of $104,925 was made by Vu Quan Anh (Chief Financial Officer) on 2025‑12‑26.
| 2025-12-26 | Vu Quan Anh | Chief Financial Officer | 1,500 0.0228% | $69.95 | $104,925 | -15.07% | ||
| 2025-12-18 | Sale | KLAUSNER ARTHUR J | director | 5,121 0.078% | $67.15 | $343,889 | -10.52% | |
| 2025-09-24 | Sale | Tactic Pharma LLC | 10 percent owner | 550,229 7.7665% | $63.61 | $35M | -11.62% | |
| 2025-07-14 | Sale | Robinson Chandler | Chief Executive Officer | 16,800 0.2513% | $40.00 | $672,020 | +38.05% | |
| 2025-07-14 | Sale | Tsuchimoto Kim R | director | 8,904 0.1332% | $40.00 | $356,171 | +38.05% | |
| 2025-07-14 | Sale | STARR CHRISTOPHER M | director | 16,800 0.2513% | $40.00 | $672,020 | +38.05% | |
| 2025-04-02 | Sale | Tactic Pharma LLC | 10 percent owner | 33,334 0.4954% | $35.00 | $1.17M | +43.39% | |
| 2024-10-28 | Radhakrishnan Karthik | Chief Financial Officer | 1,550 0.1363% | $16.25 | $25,188 | +100.90% | ||
| 2024-06-20 | Cittadine Andrew | Chief Operating Officer | 20,508 0.107% | $0.74 | $15,254 | +609.94% | ||
| 2024-06-18 | Cittadine Andrew | Chief Operating Officer | 12,000 0.0724% | $0.86 | $10,320 | +475.36% | ||
| 2024-06-17 | Cittadine Andrew | Chief Operating Officer | 12,000 0.0758% | $0.90 | $10,799 | +451.05% | ||
| 2024-06-14 | Cittadine Andrew | Chief Operating Officer | 12,000 0.0784% | $0.93 | $11,176 | +392.98% | ||
| 2024-06-13 | Cittadine Andrew | Chief Operating Officer | 12,000 0.0766% | $0.91 | $10,920 | +404.92% | ||
| 2024-06-04 | Cittadine Andrew | Chief Operating Officer | 12,000 0.0696% | $0.78 | $9,360 | +473.05% | ||
| 2024-06-03 | Cittadine Andrew | Chief Operating Officer | 12,000 0.0678% | $0.76 | $9,120 | +464.94% | ||
| 2024-05-31 | Cittadine Andrew | Chief Operating Officer | 12,000 0.0724% | $0.64 | $7,732 | +586.27% | ||
| 2024-05-30 | Cittadine Andrew | Chief Operating Officer | 12,000 0.0717% | $0.64 | $7,676 | +581.37% | ||
| 2024-05-29 | Cittadine Andrew | Chief Operating Officer | 12,000 0.0705% | $0.64 | $7,643 | +558.06% | ||
| 2022-11-15 | Cittadine Andrew | Chief Operating Officer | 10,000 0.0881% | $3.15 | $31,500 | -66.05% | ||
| 2022-11-14 | Cittadine Andrew | Chief Operating Officer | 6,053 0.0462% | $3.00 | $18,159 | -68.93% |
| Tactic Pharma LLC | 10 percent owner | 272026 4.0607% | $16.08M | 1 | 3 | <0.0001% |
| Robinson Chandler | Chief Executive Officer | 73472 1.0968% | $4.34M | 0 | 1 | |
| Tsuchimoto Kim R | director | 11486 0.1715% | $678,765.17 | 1 | 1 | <0.0001% |
| KLAUSNER ARTHUR J | director | 8762 0.1308% | $517,790.39 | 0 | 1 | |
| STARR CHRISTOPHER M | director | 5173 0.0772% | $305,698.44 | 0 | 1 | |
| Vu Quan Anh | Chief Financial Officer | 1500 0.0224% | $88,642.50 | 1 | 0 | |
| Hendricks Diane | 468750 6.9973% | $27.7M | 1 | 0 | <0.0001% | |
| Cittadine Andrew | Chief Operating Officer | 186132 2.7785% | $11M | 12 | 0 | |
| Leo Karl | 156250 2.3324% | $9.23M | 1 | 0 | <0.0001% | |
| Radhakrishnan Karthik | Chief Financial Officer | 1550 0.0231% | $91,597.25 | 1 | 0 | +100.9% |
$27,082,337 | 104 | 6.73% | $371.69M | |
$1,323,997 | 34 | 0.21% | $440.66M | |
$22,017,898 | 24 | 39.19% | $358.07M | |
$2,516,932 | 19 | -15.78% | $413M | |
$22,365,077 | 19 | -27.47% | $447.99M | |
$112,238,340 | 19 | 39.16% | $432.44M | |
$15,467,825 | 18 | 4.98% | $366.83M | |
$65,355,913 | 13 | -3.42% | $398.68M | |
$133,809,976 | 13 | 31.29% | $457.46M | |
$57,263,116 | 11 | -8.37% | $458.47M | |
$176,565 | 8 | -2.61% | $355.76M | |
$17,675,244 | 7 | 92.20% | $368M | |
$88,549,962 | 5 | -16.91% | $461.86M | |
Monopar Therapeutics Inc. (MNPR) | $12,035,408 | 5 | -37.54% | $395.88M |
$51,688 | 4 | -26.18% | $365.96M | |
$58,352 | 4 | -43.78% | $395.67M | |
$2,720,023 | 3 | -11.76% | $458.26M | |
$184,294 | 3 | -10.64% | $348.92M | |
$20,020,000 | 1 | -75.24% | $344.64M |
| Increased Positions | 55 | +152.78% | 1M | +32.62% |
| Decreased Positions | 14 | -38.89% | 227,038 | -5.24% |
| New Positions | 22 | New | 584,836 | New |
| Sold Out Positions | 5 | Sold Out | 151,788 | Sold Out |
| Total Postitions | 77 | +113.89% | 6M | +27.38% |
| Janus Henderson Group Plc | $84,979.00 | 18.39% | 1.29M | +115,000 | +9.81% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $43,513.00 | 9.42% | 659,195 | +60,000 | +10.01% | 2025-09-30 |
| Ra Capital Management, L.P. | $33,745.00 | 7.3% | 511,207 | 0 | 0% | 2025-09-30 |
| Wellington Management Group Llp | $15,279.00 | 3.31% | 231,463 | +231,463 | New | 2025-09-30 |
| Vanguard Group Inc | $13,744.00 | 2.98% | 208,218 | +121,729 | +140.75% | 2025-09-30 |
| Blackrock, Inc. | $13,450.00 | 2.91% | 203,751 | -1,418 | -0.69% | 2025-09-30 |
| Deerfield Management Company, L.P. | $10,546.00 | 2.28% | 159,765 | +159,765 | New | 2025-09-30 |
| Saturn V Capital Management Lp | $10,256.00 | 2.22% | 155,370 | +155,370 | New | 2025-09-30 |
| Tcg Crossover Management, Llc | $10,100.00 | 2.19% | 153,000 | +153,000 | New | 2025-09-30 |
| Adar1 Capital Management, Llc | $8,581.00 | 1.86% | 129,999 | +29,025 | +28.75% | 2025-09-30 |